General Atlantic, a global growth equity firm providing capital and strategic support for growth companies, led a $250m Series A financing round in Centessa Pharmaceuticals, a pharmaceutical company. Additional investors include Vida Ventures, Janus Henderson, Boxer Capital, Cormorant Asset Management, T. Rowe Price Associates, Venrock Healthcare Capital, Wellington Management, BVF Partners, EcoR1 Capital, Franklin Templeton, Logos Capital, Samsara BioCapital and LifeSci Venture. “The vision of Centessa is to build a pharmaceutical company with a unique operational framework that aims to reduce some of the key R&D inefficiencies that classical pharmaceutical companies face because of structural constraints. Our operations will be driven by an asset-centric approach, whereby each Centessa Subsidiary is solely focused on the execution of its programs with oversight from the highly experienced Centessa management team. The ambition of applying asset centricity at scale is to be able to deliver life altering medicines to patients with improved efficiency by boosting R&D productivity," Francesco De Rubertis, Centessa Pharmaceuticals Chairman.